Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-25-272532
Filing Date
2025-11-07
Accepted
2025-11-07 16:57:32
Documents
18

Document Format Files

Seq Description Document Type Size
1 S-3 d62147ds3.htm S-3 346755
2 EX-5.1 d62147dex51.htm EX-5.1 27557
3 EX-23.1 d62147dex231.htm EX-23.1 1364
4 EX-FILING FEES d62147dexfilingfees.htm   iXBRL EX-FILING FEES 38596
5 GRAPHIC g62147dsp58.jpg GRAPHIC 4274
6 GRAPHIC g62147dsp59.jpg GRAPHIC 2615
7 GRAPHIC g62147g04x33.jpg GRAPHIC 43599
8 GRAPHIC g62147g34x50.jpg GRAPHIC 40856
  Complete submission text file 0001193125-25-272532.txt   715149

Data Files

Seq Description Document Type Size
20 EXTRACTED XBRL INSTANCE DOCUMENT d62147dexfilingfees_htm.xml XML 17582
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-291388 | Film No.: 251463414
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)